You've been told this before...
Vaxinia was jointly undertaken at the following Australian hospitals so the rebate was more substantial:
https://clinicaltrials.gov/study/NCT05346484?intr=vaxinia&rank=1
onCARlytics was only conducted stateside:
https://clinicaltrials.gov/study/NCT06063317?intr=oncarlytics&rank=1
Azer-Cel was only conducted stateside until in January 2025 when an Australian trial site was launched:
You will see limited rebate for FY2024 and this is why IMU only accrued ~$4.5m... The reason the Australian Azer-Cel trial sites were launched was to reduce the cost of the trial and increase the potential for the R&D rebate.
You've been told this before...Vaxinia was jointly undertaken at...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.002(18.2%) |
Mkt cap ! $97.07M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.1¢ | $625.7K | 50.56M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 5795292 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 3258567 | 9 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |